Navigation Links
aTyr Pharma to Present at Japan Biopharma Partnering Conference
Date:9/24/2009

SAN DIEGO, Calif., Sept. 24 /PRNewswire/ -- aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the Japan Biopharma Conference in Tokyo on Tuesday October 6. Jeff Watkins, CEO of aTyr Pharma, will provide an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

According to Cheryl Quinn, Director of Business Development at aTyr Pharma, "Our broad multi-asset portfolio of novel biotherapeutics can help pharmaceutical companies rapidly build out their biologics pipeline. We look forward to taking part in the Japan Biopharma conference, as well as meeting potential partners from Japan and Asia and to explore mutually beneficial opportunities."

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
3. Kaiser Permanente Recognized by J.D. Power and Associates as Highest in Customer Satisfaction Among Mail-Order Pharmacies
4. Cambridge Healthtech Institute and Bio-IT World Launch a New eNewsletter: Pharma Services News
5. PharmAthene to Present at The Maxim Group Growth Conference September 29, 2009
6. Pharmaceutical, Biotech Research Companies Support Newark Rx Assistance Program
7. Reportlinker Adds Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing, 3rd Edition Report
8. Cardinal Health Introduces Expanded Suite of Services to Help Hospital Pharmacies Improve Cost Containment, Workflow, Patient Safety
9. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
10. Baxa IntelliFlowRx(TM) Upgrades Expand Pharmacy Capabilities
11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, ... to her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, ...
(Date:1/16/2017)... PARK CITY, UT (PRWEB) , ... January 16, 2017 , ... ... expensive disease not only to treat, but to test for, as well. The money ... $88.7 billion every year.(1) Doctors in the U.S. screen patients for cancer more than ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as a ... honored for their accomplishments in the field of midmarket financial software. , Members of ... and innovation. Selection is not based on revenue and those firms chosen represent a ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated ... avenues for purchase. , The 2017 edition has wide jaws that will accommodate nails ... boomers as well as diabetics. This handle is reinforced for extra strength when pressing down ...
(Date:1/15/2017)... ... January 15, 2017 , ... San ... in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and ... the award process. Results were announced the magazine’s January 2017 issue . ...
Breaking Medicine News(10 mins):
(Date:1/15/2017)... , January 16, 2017 Le ... innovants à base de collagène pour la régénération de tissus ... au poste de directeur général avec effet immédiat. ... Bill est un ... a occupé plusieurs postes de gestion générale et de direction ...
(Date:1/13/2017)... , Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... VP of Corporate Finance and Investment Banking at Eli Lilly ... effective immediately. Mr. Bott brings over 28 years of senior ... ... Martin Bott has established a significant leadership position in ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology: